Skip to main content
    U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.75
    -0.98 (-3.81%)

    Market Cap: $1.41B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    39%(15/38)
    Avg Surprise
    -7.75%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.41
    Range$-0.17 - $0.86
    7 analysts
    Revenue Consensus
    $122M
    Range$104M - $138M
    8 analysts
    Last 12 of 39 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.41$-0.17 - $0.86--7--
    Sep 26
    Reported Nov 4
    		$-0.03$0.05--160.00%Miss7
    5
    0
    30d
    		+95.7%
    Jun 26
    Reported Aug 5
    		$-0.28$-0.38$-0.61 - $-0.16+26.32%Beat8
    5
    0
    30d
    		+73.3%
    Mar 26
    Reported May 6
    		$-0.47$-0.48$-0.62 - $-0.11+2.08%Beat8
    2
    0
    30d
    		+48.9%
    Dec 25
    Reported Mar 2
    		$-0.53$-0.48$-0.74 - $-0.31-9.94%Miss7
    0
    1
    30d
    		+33.8%
    Sep 25
    Reported Nov 6
    		$-0.69$-0.68$-0.79 - $-0.52-1.47%Miss7
    0
    4
    30d
    		-25.5%
    Jun 25
    Reported Aug 7
    		$-1.05$-0.82$-0.94 - $-0.60-28.05%Miss7
    1
    3
    30d
    		-15.4%
    Mar 25
    Reported May 12
    		$-0.92$-0.79$-0.96 - $-0.37-16.46%Miss6
    1
    2
    30d
    		+5.2%
    Dec 24
    Reported Mar 10
    		$-0.80$-0.72$-0.97 - $-0.55-11.11%Miss7
    0
    1
    30d
    		-11.1%
    Sep 24
    Reported Nov 6
    		$-0.55$-0.82$-0.91 - $-0.76+32.93%Beat7
    No revisions (30d)
    		+19.1%
    Jun 24
    Reported Aug 13
    		$-0.91$-0.83$-0.90 - $-0.77-9.64%Miss5
    1
    0
    30d
    		+11.7%
    Mar 24
    Reported May 13
    		$-0.97$-0.87$-0.99 - $-0.75-11.49%Miss5
    1
    0
    30d
    		+25.4%
    Dec 23
    Reported Mar 14
    		$-0.72$-0.68$-0.74 - $-0.61-5.88%Miss5
    No revisions (30d)
    		+41.0%

    Key Metrics

    Valuation
    P/E Ratio-18.89EV/EBITDAN/A
    Price/FCF-9.48xFCF Yield-10.55%
    Profitability
    Profit Margin-26.30%Operating Margin9.36%
    ROE-1481.00%ROIC-73.72%
    Financial Health
    Debt/Equity-1.53xInterest Coverage-2.78x
    Current Ratio3.40xQuick Ratio3.06x
    Trading Statistics
    Beta1.64Avg Volume1.39M
    52-Week High$50.8152-Week Low$16.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$31.59
    SMA 20$33.72
    SMA 50$38.78
    SMA 200$31.56
    EMA 10$30.65
    EMA 20$33.25
    EMA 50$36.88
    EMA 200$33.07

    MACD

    Line: -3.08Signal: -2.33Hist: -0.75

    ADX

    ADX: 40.5+DI: 9.6-DI: 43.3

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$34.59

    Bollinger Bands

    Upper Band$40.79
    Lower Band$26.65
    %B Position4193%(Upper)
    Band Width-0.13

    RSI (14-Day)

    Oversold
    18.1

    Momentum Oscillators

    Stoch %K7.2
    Stoch %D16.6
    Williams %R-97.1
    ROC (10d)-28.2%
    Momentum-9.74
    CCI (20d)-273.5
    MFI (14d)35.1

    Volatility Measures

    ATR (14d)$2.24(9.1%)
    StdDev (20d)3.53
    Hist Vol76.4%(High)

    Volume Flow

    VWAP$25.16
    OBV59.9M
    AD Line31.7M
    CMF (20d)-0.277

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio1.4x
    VWMA (20d)$32.40

    Pivot Points

    R3$32.17
    R2$30.62
    R1$28.17
    Pivot Point$26.62
    S1$24.17
    S2$22.62
    S3$20.17

    Advanced Oscillators

    TSI-47.61
    Ultimate Osc30.8
    KST-207.68

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$89.00M$72.46M$50.96M$37.84M$27.48M$24.21M$20.25M$24.57M$25.20M$21.85M$18.78M$23.53M
    Cost of Revenue$7.50M$6.57M$4.14M$3.29M$3.28M$3.55M$2.33M$2.47M$2.45M$2.23M$1.73M$2.29M
    Gross Profit$81.50M$65.88M$46.82M$34.55M$24.20M$20.66M$17.92M$22.09M$22.75M$19.62M$17.05M$21.24M
    Operating Expenses$73.17M$65.77M$67.08M$53.66M$51.59M$62.11M$54.84M$49.75M$40.30M$45.46M$42.79M$35.85M
    R&D$25.96M$17.34M$15.60M$14.31M$14.01M$18.91M$19.87M$14.89M$11.36M$15.40M$15.49M$11.30M
    SG&A$47.21M$48.44M$51.49M$39.35M$37.58M$43.20M$34.97M$34.86M$28.94M$30.06M$27.30M$24.55M
    Operating Income$8.33M$111,000$-20,263,000$-19,115,000$-27,386,000$-41,448,000$-36,914,000$-27,658,000$-17,545,000$-25,839,000$-25,740,000$-14,609,000
    Interest Income$607,000$599,000$608,000$903,000$979,000$1.30M$2.11M$2.75M$2.60M$1.71M$1.61M$1.54M
    Interest Expense$4.84M$4.89M$4.18M$3.77M$3.37M$4.13M$4.07M$3.89M$2.72M$3.46M$2.45M$3.59M
    Income Before Tax$-446,000$-8,722,000$-28,346,000$-26,639,000$-34,401,000$-48,925,000$-43,451,000$-34,863,000$-23,582,000$-33,365,000$-32,232,000$-22,162,000
    Income Tax Expense$1.02M$5.63M$-4,772,000$-275,000$-1,054,000$1.01M$392,000$2.65M$91,000$38,000$54,000$3.85M
    Net Income$-1,462,000$-14,351,000$-23,574,000$-26,364,000$-33,347,000$-49,940,000$-43,843,000$-37,512,000$-23,673,000$-33,403,000$-32,286,000$-26,016,000
    EBITDA$5.03M$-4,838,000$-22,117,000$-23,067,000$-31,925,000$-45,962,000$-41,400,000$-34,726,000$-24,860,000$-31,424,000$-32,193,000$-20,972,000
    EBIT$3.78M$-4,434,000$-24,769,000$-23,770,000$-32,007,000$-46,092,000$-41,497,000$-33,721,000$-23,460,000$-31,612,000$-31,400,000$-20,114,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about URGN

    Government Contracts

    Gov Obligations (TTM)
    $118064
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24626N0375Department of Veterans AffairsDepartment of Veterans Affairs$32844Dec 9, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    URGN Valuation and Fair Value

    P/E
    -18.9x
    Forward P/E
    15.6x
    P/FCF
    -9.5x
    PEG
    0.0x
    P/B
    -10.0x
    See GNG's fair value

    URGN Profitability: Margins, ROIC and FCF

    Gross margin
    91.4%
    Operating margin
    9.4%
    Net margin
    -26.3%
    ROIC
    -73.7%
    ROE
    -1481.0%
    FCF margin
    -52.8%
    FCF yield
    -10.6%

    URGN Competitors

    CompanyTicker
    Phibro Animal Health CorporationPAHC
    Enovis CorpENOV
    U.S. Physical Therapy, Inc.USPH
    Rapport Therapeutics, Inc. Common StockRAPP
    Pacira BioSciences, Inc.PCRX
    Nutex Health IncNUTX
    Immunocore Holdings LtdIMCR
    Pennant Group IncPNTG

    Sector: Healthcare

    URGN Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    6
    Hold
    1
    Sell
    0
    Strong Sell
    0

    URGN Bull Case vs Bear Case

    Bull case

    • URGN grew quarterly revenue 223.9% year over year.
    • 87.5% of URGN's analyst ratings are Buy or Strong Buy.

    Bear case

    • URGN has a -26.3% net profit margin.
    • URGN beat EPS estimates in 25.0% of its last 8 reported quarters.

    URGN Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -24.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.41

    URGN Earnings Date

    URGN reports Mar 1, 2027, after the close. The date is confirmed.

    URGN Earnings Call

    The latest URGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    URGN ETF Holders

    GNG tracks 6 ETFs that hold URGN. The largest weights:

    1. ARK Israel Innovative Technology ETF (IZRL), 1.58% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.13% of the fund
    3. iShares Biotechnology ETF (IBB), 0.10% of the fund
    4. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.04% of the fund
    5. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    Open the ETF Stock Exposure tool for URGN

    See insider activity

    Frequently Asked Questions About URGN

    When does URGN report earnings?

    UroGen Pharma Ltd (URGN) is confirmed to report earnings on Mar 1, 2027.

    Does URGN pay dividends?

    UroGen Pharma Ltd (URGN) does not currently pay a regular dividend.

    What is URGN's market cap?

    UroGen Pharma Ltd (URGN) has a market capitalization of $1.41B with a current stock price of $24.75.

    Related stocks

    Sector: Healthcare

    All stocks starting with U

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In